Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

Phase 4

Completed

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT00290394
• Lead Sponsor: Baskent University

Brief Summary

The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.

Detailed Description

The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks' treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.

Study Timeline

• Status Verified: 2004-03
• Study Start: 2004-03
• Study Completion: 2004-08
• Study First Submitted: 2006-02-09
• Study First Submitted QC: 2006-02-09
• Last Update Submitted: 2006-02-09
• Study First Posted: 2006-02-13
• Last Update Posted: 2006-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Blood pressure of patients were in normotensive limits according to the JNC VII
• Diabetes mellitus treated with oral antidiabetics or diet

Read More

Exclusion Criteria

• Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease
• Anti-hypertensive treatment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.

Trial Locations

Locations (1)

Baskent University Ankara Hospital; 🇹🇷 Ankara, Turkey